Better Therapeutics, Inc. BTTX
- Market cap
- $850.0K
- P/E
- 0.0×
Follow BTTX
Target Price Range
Analyst price targets
Free account| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | 4.41 | 0.91 |
Analyst estimates 2023–2025 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | 29.40 | 5.13 |
High Price
|
|||
| — | — | — | — | — | — | — | 2 | 44 | 54 |
Employees
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | 0 | — | — |
Revenue
|
|||
| — | — | — | — | — | — | — | 100.00% | 0.00% | 0.00% |
Gross Margin
|
|||
| — | — | — | — | — | — | — | (6) | (40) | (40) |
EBT
|
|||
| — | — | — | — | — | — | — | (77,925.00%) | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | 0 | — | — | (6) | (40) | (40) |
Net Income
|
|||
| — | — | — | — | — | — | — | 0 | 2 | 3 |
Depreciation
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | (3.11) | (1.69) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | (0.58) | (2.37) | (1.23) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | (0.23) | (0.08) | (0.05) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | (0.81) | (2.46) | (1.28) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | (0.68) | 2.83 | (0.04) |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | 10 | 13 | 24 |
Shares
|
|||
| — | — | — | — | — | — | — | 0.00 | — | — |
PE Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | — | — |
PS Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | — | — |
PB Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | — | — |
EV/Sales
|
|||
| — | — | — | — | — | — | — | 0.00 | — | — |
EV/FCF
|
|||
| — | — | — | — | — | — | — | (6) | (31) | (29) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | (2) | (1) | (1) |
Capex
|
|||
| — | — | — | — | — | — | — | (8) | (32) | (30) |
FCF
|
|||
| — | — | — | — | — | — | — | 0 | 41 | 5 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | 1 | 10 | 15 |
Total Debt
|
|||
| — | — | — | — | — | — | — | 1 | (31) | (1) |
Net Debt
|
|||
| — | — | — | — | — | — | — | (7) | 37 | (1) |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | (247.19%) | (140.67%) | (107.60%) |
ROA
|
|||
| — | — | — | — | — | — | — | 0.00% | (337.52%) | 0.00% |
ROIC
|
|||
| — | — | — | — | — | — | — | (52.69%) | (269.24%) | (221.99%) |
ROE
|
|||
Better Therapeutics, Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| LYRA Lyra Therapeutics, Inc. | $870.0K | 0.0× | Compare |
| ZVSA ZyVersa Therapeutics, Inc. | $970.0K | 0.0× | Compare |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR | $700.0K | 0.0× | Compare |
| SEELQ Seelos Therapeutics, Inc. | $700.0K | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| MNTRQ 9 Meters Biopharma, Inc. | $1.0M | 0.0× | Compare |
| ATXI Avenue Therapeutics, Inc. | $680.0K | 0.0× | Compare |
| BPTH Bio-Path Holdings, Inc. | $1.1M | 0.0× | Compare |
| CYTOF Altamira Therapeutics Ltd. | $1.1M | 0.0× | Compare |
Better Therapeutics, Inc. (BTTX) Latest News
14 Mar
Better Therapeutics, Inc. announces termination of employees and exploration of strategic alternatives, including possible wind-down of the company. Securities to be delisted from Nasdaq. The announcement of termination of employees, exploration of strategic alternatives, and delisting of securities are significant events that could fundamentally alter the company's trajectory and investor sentiment.
5 Mar
Better Therapeutics partners with ACLM to offer one million prescriptions of AspyreRx to underserved communities affected by diabetes. The partnership with ACLM and the initiative to offer one million prescriptions of AspyreRx have the potential to significantly impact Better Therapeutics' future market performance and strategic positioning.
4 Mar
Better Therapeutics announces acceptance of late-breaking abstract for its AspyreRx pivotal trial 180 day outcomes and participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). The announcement of significant outcomes data and participation at a prestigious conference is likely to have a significant impact on Better Therapeutics' future and market performance.
1 Mar
RedChip Companies will air interviews with Better Therapeutics, Inc. and Biotricity, Inc. on Bloomberg TV. The article discusses significant developments in Better Therapeutics, Inc. and Biotricity, Inc. that could have a major impact on their future performance and market positioning.
22 Feb
Better Therapeutics, Inc. (BTTX) has received Breakthrough Therapy Designation from the FDA for its cognitive behavioral therapy (CBT) platform aimed at treating cardiometabolic diseases. This designation is intended to expedite the development and review process for therapies that demonstrate significant potential in addressing serious conditions. The company aims to leverage this status to enhance its market position and accelerate the availability of its innovative treatment options. The FDA's Breakthrough Therapy Designation is expected to significantly enhance the company's development timeline and market positioning.
20 Feb
Better Therapeutics receives FDA Breakthrough Device Designation for CBT platform targeting advanced liver disease. Breakthrough Device Designation has potential to significantly impact company's future and market performance.
6 Feb
Better Therapeutics signs rebate agreement with one of the largest Pharmacy Benefit Managers in the US for its AspyreRx diabetes treatment. The rebate agreement with a major PBM is expected to significantly impact Better Therapeutics' future market performance and coverage for its diabetes treatment.
18 Jan
David Perry bought more shares in Better Therapeutics. Insider transactions and ownership indicate positive outlook for Better Therapeutics.
17 Jan
AspyreRx plus standard of care is more effective and less costly than standard of care alone for type 2 diabetes, according to a cost-effectiveness analysis. The study results demonstrate a significant impact on Better Therapeutics, Inc. (BTTX) future and market performance by showing the potential for AspyreRx to be a more effective and cost-saving treatment for type 2 diabetes.
4 Jan
Better Therapeutics and Glooko partner to integrate AspyreRx for treating Type 2 Diabetes in the US. Partnership with Glooko to integrate AspyreRx has the potential to significantly impact Better Therapeutics' market reach and product adoption.
3 Jan
Insiders at Better Therapeutics, Inc. added US$6.57m of stock to their holdings over the last 12 months. Insiders' increased optimism and significant stock purchases suggest a potentially significant impact on the company's future.
2 Jan
Better Therapeutics seeks FDA Breakthrough Device Designation for digital therapeutic platform to treat liver disease. Potential FDA Breakthrough Device Designation could significantly impact Better Therapeutics' future product offerings and market expansion.
28 Nov
Better Therapeutics extends cash runway and implements cost reductions to support commercial traction of AspyreRx in type 2 diabetes. The financial initiatives and cost-saving measures are expected to have a significant impact on Better Therapeutics' future performance and market positioning.
14 Nov
Better Therapeutics receives Frost & Sullivan's 2023 Technology Innovation Leadership Award for its AspyreRx app to treat type 2 diabetes. Recognition by Frost & Sullivan and FDA approval for AspyreRx could significantly impact Better Therapeutics' future growth and market performance.
9 Nov
Better Therapeutics obtained FDA authorization for AspyreRx to treat adults with type 2 diabetes and announced commercial launch. Company reported Q3 2023 financial results and provided business updates. FDA authorization for AspyreRx, completion of enrollment in real-world evidence program, new patent issued, commercial launch, study results published, and new data on clinical outcomes show significant impact on future and market performance.
8 Nov
Better Therapeutics to release Q3 2023 financial results and business update on November 09, 2023. Significant impact likely on future and performance due to FDA authorization for AspyreRxTM and potential improvements in patient health and healthcare costs.
26 Oct
Better Therapeutics to showcase AspyreRx at the American College of Lifestyle Medicine's 2023 Annual Conference. The introduction of AspyreRx, the first prescription-only digital treatment for type 2 diabetes, at a major medical conference is expected to have a significant impact on Better Therapeutics' future and market performance.
16 Oct
Better Therapeutics launches AspyreRx, the first FDA-authorized digital behavioral therapeutic device for adults with Type 2 Diabetes. The launch of AspyreRx has the potential to significantly impact Better Therapeutics' future performance and market positioning.
11 Oct
Better Therapeutics announces new data showing significant reduction in HbA1c with AspyreRx and GLP-1 receptor agonists for treating Type 2 Diabetes. The new data on AspyreRx and GLP-1 receptor agonists could have a significant impact on Better Therapeutics' future market performance and competitive positioning.
5 Oct
Better Therapeutics announces positive results from LivVita Liver Disease Study, plans to seek FDA Breakthrough Device Designation by end of 2023. Positive study results and potential FDA designation could significantly impact Better Therapeutics' future and market performance.
28 Sep
Better Therapeutics completes enrollment of 1,000 participants in real-world evidence program evaluating long-term effectiveness of AspyreRx in Type 2 Diabetes. The completion of enrollment and upcoming commercial launch of AspyreRx is expected to have a significant impact on Better Therapeutics' future performance and market positioning.